Multiple Sclerosis Drugs - Haiti

Haiti

Highlights

In Haiti, the Multiple Sclerosis Drugs market is expected to witness a significant increase in revenue.
By 2024, the projected revenue is estimated to reach US$2.19m.
This growth is anticipated to continue with an annual growth rate (CAGR 2024-2029) of 0.83%, leading to a market volume of US$2.28m by 2029.
It is important to note that in the global market, United States is expected to generate the highest revenue, amounting to US$11.77bn in 2024.
Despite the limited access to healthcare resources in Haiti, there is a growing demand for affordable and accessible multiple sclerosis drugs in the country.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Multiple Sclerosis Drugs market in Haiti has been experiencing a steady growth in recent years.

Customer preferences: Patients suffering from Multiple Sclerosis in Haiti have been showing a growing preference for disease-modifying therapies. This is due to the fact that these drugs not only reduce the frequency and severity of relapses but also slow down the progression of the disease. Patients are also showing a preference for oral medications over injectables due to the convenience they offer.

Trends in the market: The Multiple Sclerosis Drugs market in Haiti has been growing due to the increasing prevalence of the disease in the country. The market has seen a shift towards disease-modifying therapies, which have been gaining popularity among patients. There has also been an increase in the availability of oral medications, which has led to a shift away from injectables. The market has also seen an increase in the number of new entrants, which has led to increased competition.

Local special circumstances: Haiti has a relatively low prevalence of Multiple Sclerosis compared to other countries in the region. However, the country has a large population, which means that there is still a significant number of patients suffering from the disease. The country also has a relatively underdeveloped healthcare system, which means that access to healthcare can be a challenge for some patients.

Underlying macroeconomic factors: Haiti is one of the poorest countries in the Western Hemisphere and has been struggling with political instability and economic challenges for many years. The country has a high poverty rate, which means that many patients may not be able to afford expensive medications. The country also has a relatively low GDP per capita, which means that the market for high-end medications may be limited. However, the country has been experiencing some economic growth in recent years, which may lead to an increase in the availability of healthcare services and an increase in the market for Multiple Sclerosis Drugs.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.